Affiliations: Domus Medica, Utrecht, The Netherlands
Note: [] Address for correspondence: D. Bijl, MD, Editor in Chief, Geneesmiddelenbulletin (Dutch Drug Bulletin), Redactie Geneesmiddelenbulletin, Domus Medica, Postbus 2190, 3500 GD Utrecht, The Netherlands. Tel.: +31 030 2823360; E-mail: dick.bijl@hetnet.nl
Abstract: At the time of the outbreak of the pandemic of New Influenza A (H1N1) pandemic influenza vaccines became available via an accelerated registration procedure. In 2005 large stocks of the neuraminidase inhibitor oseltamivir were built up in the Netherlands and other western countries. There was considerable doubt about the efficacy of this medicine. Initially reported positive effects of the drug were largely based on unpublished research, which was sponsored by the manufacturer and was partially written by ghostwriters. There now have been reports of rare and serious side effects. The first reports on the severity of the pandemic in Australia and New Zealand indicated a mild course.
